Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607989 | 0.89 | CTSK (0.45) | CTSKCTSSKMT2AMEN1ACHE | |
| SCHEMBL21900932 | 0.87 | CTSK (0.46) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL22244378 | 0.84 | CTSK (0.50) | CTSKCTSSKMT2AMEN1GABRB1 | |
| SCHEMBL4715472 | 0.82 | CTSK (0.43) | CTSKCTSSKMT2ACTSL | |
| SCHEMBL4714909 | 0.82 | CTSK (0.43) | CTSKCTSSKMT2ACTSL | |
| SCHEMBL2793927 | 0.81 | KMT2A (0.49) | KMT2AMEN1 | |
| SCHEMBL21900831 | 0.81 | CTSK (0.50) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL28264427 | 0.80 | MAPT (0.48) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL1094296 | 0.80 | KMT2A (0.44) | KMT2AMEN1ACHECTSLSLC6A9 | |
| SCHEMBL4116055 | 0.79 | SMYD3 (0.53) | CTSKCTSSKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | HITGEN INC. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | HITGEN INC. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3640242-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | Hitgen Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | ROCK1, ROCK2, RHOA | CTSK 1352/4885CTSS 2946/4885KMT2A 2008/4885 |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | ROCK1, ROCK2, RHOA | CTSK 1352/4885CTSS 2946/4885KMT2A 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.